Schering CEO: Takeover prices reflect demand for quality drugs

11/1/2006 | MarketWatch

The prices pharmaceutical companies are paying to take over other companies is indicative of the difficulty they are having in acquiring quality drug candidates, Schering-Plough CEO Fred Hassan said. He called the prices "breath-taking" and the amounts "unthinkable five years ago."

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC